BIOG.Y Stock Overview
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr9.72 |
| 52 Week High | kr12.09 |
| 52 Week Low | kr8.75 |
| Beta | 0.54 |
| 1 Month Change | -19.60% |
| 3 Month Change | -4.99% |
| 1 Year Change | 15.99% |
| 3 Year Change | -4.29% |
| 5 Year Change | 1.25% |
| Change since IPO | 49.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOG.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.6% | -2.5% | -3.2% |
| 1Y | 16.0% | -3.7% | 19.3% |
Return vs Industry: BIOG.Y exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: BIOG.Y underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| BIOG.Y volatility | |
|---|---|
| BIOG.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOG.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOG.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 210 | Theresa Agnew | www.biogaia.com |
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia AB (publ) Fundamentals Summary
| BIOG.Y fundamental statistics | |
|---|---|
| Market cap | US$1.10b |
| Earnings (TTM) | US$33.42m |
| Revenue (TTM) | US$118.60m |
33.0x
P/E Ratio9.3x
P/S RatioIs BIOG.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOG.Y income statement (TTM) | |
|---|---|
| Revenue | kr1.30b |
| Cost of Revenue | kr346.32m |
| Gross Profit | kr950.19m |
| Other Expenses | kr584.84m |
| Earnings | kr365.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | 3.62 |
| Gross Margin | 73.29% |
| Net Profit Margin | 28.18% |
| Debt/Equity Ratio | 0% |
How did BIOG.Y perform over the long term?
See historical performance and comparison